Johnson & Johnson’s Q1 Boom Highlights Pharma’s Focus on Money, Not Cures
-
LN24 / 8 months
- 0
- 3 min read
Johnson & Johnson once again delivered higher-than-expected profits in the first quarter, driven largely by its high-priced cancer drugs and expanding pharmaceutical portfolio — a familiar story in an industry known more for profit margins than affordability. The company increased its revenue forecast for the year by $700 million, crediting part of the gain to […]